medigraphic.com
ISSN 1995-9427 (Print)

2012, Number 2

<< Back Next >>

Invest Medicoquir 2012; 4 (2)

Monoclonal gammopathies caracterization

Howland ÁI, Hernández PJC, Becherán ML, Luna CC, Figueredo PY, Fonseca TN

Language: Spanish
References: 37
Page: 174-187
PDF size: 413.49 Kb.


ABSTRACT

Introduction. At present there exists clinical interest in the study of the monoclonal gammopathies. This bases on the possibility of studying different illnesses as the malignant diseases and the infections. Methods.The following study was realized between the 2010 and 2011, and there were analyzed the patient's proteinograms of the Medical & Surgical Research Center in order to characterize the monoclonal gammopathies that appeared in the same ones (11.3 %). The middle age of the patients was 59 years with major predominance in females. There decided the frequency of presentation of the monoclonal gammopathies and the same ones were described in terms of demographic variables: sex and age. Results. In 52.7 % of the patients a diagnostic estimation was consisting on the monoclonal gammopathies neither in the clinical histories, nor proposal of evolutionary pursuit. Conclusions. The most frequent cause of monoclonal gammopathies was that of uncertain meaning, and the multiple mieloma followed him.


REFERENCES

  1. Suardíaz J, Cruz C, Colina A. Laboratorio Clínico. La Habana: Editorial Ciencias Médicas; 2004.p. 32-38.

  2. Llompart I, Maffiotte E, Belmonte M, Barcelo B, Riera B, Sastre P. Estudio retrospectivo de 1.193 componentes monoclonales detectados en Palma de Mallorca. Rev Lab Clin. 2010;3(2):69–75.

  3. Dispenzieri A, Rajkumar VS, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, et al. Treatment of Newly Diagnosed Multiple Myeloma based on Mayo Stratification of Myeloma and Riskadapted Therapy (mSMART): Consensus Statement. Mayo Clin Proc. 2007;82(3):323-41.

  4. Bladé J. Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2006;355(3):2765-8.

  5. Amor M, Sánchez P, Diez M, Batlle FJ, Martínez A. Gammapatías Monoclonales. Guías Clínicas (revista en Internet) 2006 (consultado en mayo de 2011): Disponible en: URL: http://www.guiasclinicas.es/sit/

  6. Vázquez FJ, Funtowicz G, García H, Schutz N, Fantl D, Nucifora E. Compromiso nodular hepático secundario a mieloma múltiple. Medicina. 2010;70(4):311-5.

  7. Kyle RA, Therneau TM, Rajkumar V, Larson DR, Plevak MF, Oxford JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-9.

  8. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with new diagnosed Multiple Myeloma. Mayo Clin Proc. 2003;78(1):21–33.

  9. Kyle RA, Therneau TM, Rajkumar SV, Oxford JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-69.

  10. Kyle RA, Remstein ED, Therneau TM, et al. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. N Engl J Med. 2007;356(25):2582-90.

  11. Sansó FJ, Alonso P, Torres RM. Mortalidad por cáncer en Cuba. Rev. Cubana Salud Pub. 2010;36(1):78-94.

  12. Martín AA, Soriano JL, Galán YH, Rodríguez AJ y Fernández LM. Incidencia de las leucemias y los mielomas en Cuba (1986-1990). Rev Cubana Oncol. 1998;14(1):63-70.

  13. Bladé J, Rosiñol L. Mieloma múltiple. En: Sans-Sabrafen J, Besses Raebel C, Vives Corrons JL, Editores. Clínica Hematológica. 5ed. Barcelona: Elsevier España 2006.p. 636-7.

  14. Gómez D, Cano R, Cedillo JL, Garcés OM, Limón A, López M. Guías mexicanas de diagnóstico y recomendaciones terapéuticas para mieloma múltiple (2009). Hematología. 2010;11(1):40-62.

  15. The Internacional Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders. A report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.

  16. Bladé J, López-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992;81(3):391–4.

  17. Carnot J, Castro R. Mieloma múltiple diagnóstico, estudio y tratamiento. Manual de Prácticas Médicas HCQ “Hermanos Ameijeiras”, II ed, 2008 (consultado en julio de 2011). Servicio de Hematología. Disponible en: URL: http://www.hospitalameijeiras.sld.cu/hha/mpm/documentos/HEMATOLOGIA/PA/MIELOMA%20MULTIPLE.pdf.

  18. Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undeterminated significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010;85(10):945-8.

  19. Corral A, Castañeda IE, Barzaga M, Santana MC. Determinantes sociales en la diferencia de mortalidad entre mujeres y hombres en Cuba. Rev Cubana Salud Pub. 2010;36(1):66-77.

  20. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701-5.

  21. Batuecas M, Piqueras JA, Carballo F. Gammapatía monoclonal: un diagnóstico frecuentemente soslayado. Rev Clin Esp. 2005;205(5):207-11.

  22. Durie BG, Kyle RA, Belch A, Bensinger W, Bladé J, Boccadoro M, et al. Myeloma Management Guide lines: a consensus report from the Scientific Advisors of the Internacional Myeloma Foundation. The Hematol J. 2003;4(6):397–98.

  23. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010;150(1):28-38.

  24. Corral A, Castañeda IE, Barzaga M, Santana MC. Determinantes sociales en la diferencia de mortalidad entre mujeres y hombres en Cuba. Rev Cubana Salud Pub. 2010;36(1):66-77.

  25. Gómez R, Clarós IJ, Rubio S, Zanabili Y. Leucemia de células plasmáticas secundaria como evolución de gammapatía monoclonal de significado incierto. An. Med. Interna (Madrid) (revista en Internet). Mar 2003 (consultado en feb. 2010) 20(3):57-58. Disponible en: URL: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992003000300012&lng=es.

  26. García-Sanz R, Mateos MV, San Miguel JF. Mieloma múltiple. Med Clin. 2007;129(3):104-15.

  27. Jaskowski TD, Litwin CM, Hill HR. Detection of Light Chain Monoclonal Proteins in Human Serum: Automated Immunoassay versus Immunofixation Electrophoresis. Clin Vaccine Immunol. 2006;13(2):277–80.

  28. Dispenzieri A, Kyle RA, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum free-light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.

  29. Prabhakaran S, Gutin PH, Holodny A, Raizer JJ. Isolated primary intracerebralmycetoma: presenting as a mass lesion in a patient with prostate cancer and multiple myeloma. J Neurooncol. 2005;71(1):49-52.

  30. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best PractRes Clin Haematol. 2007;20(4):637-64.

  31. Oterino A. Actualización. Neuropatías periféricas. JANO (página en Internet). 6-12 de junio de 2008 (consultada en octubre de 2011);699(1):20-24. Disponible en: URL: http:// www.jano.es.

  32. Jadoon NA, Shahzad MA, Yaqoob R, HussainM, Ali N.Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positiveassociation. Virol J. 2010;7(6):304-8.

  33. García RD, Alonso MM, Oramas J, Alonso B, Batista N. Sepsis de repetición en un paciente con gammapatía monoclonal de significado incierto. An Med Interna. (Madrid) (revista en Internet). Sep 2006 (consultado en marzo de 2010);20(9):452. Disponible en: URL:

  34. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992006000900015&lng=es. http://dx.doi.org/10.4321/S0212-71992006000900015

  35. Amara S, Dezube BJ, Aboulafia DM. Monoclonal Gammopathy and HIV. Clin Infect Dis. 2006;43(9):1198-205.

  36. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101(10):3818-26.

  37. Gousseff M, Arnaud L, Lambert M, Hot A, Hamidou M, Duhaut P. Síndrome de extravasación capilar sistémica. Ann Intern Med. 2011;154(7):464-71.




2020     |     www.medigraphic.com